Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. (NCT06697301)

🧪 Interventions in This Study

• EIK1001 (DRUG)
• Pembrolizumab (KEYTRUDA® ) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (107 Sites)

Showing the first 25 of 107 sites.

• Ironwood Cancer & Research Centers — Chandler, Arizona
• Genesis Cancer and Blood Institute — Hot Springs, Arkansas
• Helios Clinical Research — Los Angeles, California
• Providence Medical Foundation — Santa Rosa, California
• UCHealth Memorial Hospital Central — Colorado Springs, Colorado
• Bioresearch Partner — Hialeah, Florida
• The Center for Cancer and Blood Disorders — Bethesda, Maryland
• MidAmerica Cancer Care — Kansas City, Missouri
• Washington University School of Medicine in St. Louis — St Louis, Missouri
• Gabrail Cancer Center Research LLC — Canton, Ohio
• University of Pittsburgh Medical Center(UPMC)-Hillman Cancer Center — Pittsburgh, Pennsylvania
• Cancer Care Wollongong — Wollongong, New South Wales
• Icon Cancer Centre Chermside — Chermside, Queensland
• Southern Adelaide Local Health Network Incorporated Flinders Medical Centre — Bedford Park, South Australia
• Eastern Health — Box Hill, Victoria
• Peninsula and South Eastern Haematology and Oncology Group — Frankston, Victoria
• Universitätsklinikum Graz — Graz, Styria
• Universitair Ziekenhuis Antwerpen — Edegem, Antwerpen
• Cliniques Universitaires Saint-Luc — Brussels, Brussels Capital
• Centre Hospitalier Universitaire Universite Catholique de Louvain - Site Godinne — Yvoir, Namur
• Universitair Ziekenhuis Leuven - Campus Gasthuisberg — Leuven, Vlaams Brabant
• Algemeen Ziekenhuis Groeninge - Campus Kennedylaan — Kortrijk, West-Vlaanderen
• Vitaz Primary Location — Sint-Niklaas,
• Sunnybrook Research Ins<tute — Toronto, Ontario
• Masaryk Memorial Cancer Institute — Brno, Brno

📞 Contact the Study Coordinator

Phone: (516) 675-6163

Email: Kazak@eikontx.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Melanoma

• Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial — Fairhope, Alabama
• Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery — Birmingham, Alabama
• Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma — Mobile, Alabama
• A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma — Scottsdale, Arizona
• A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma — Pittsburgh, Pennsylvania
• Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors — St Louis, Missouri

Explore by condition: All Advanced Melanoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.